

JosÃ© M Zijlstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7695570/publications.pdf>

Version: 2024-02-01

97
papers

5,530
citations

172457

29
h-index

85541

71
g-index

100
all docs

100
docs citations

100
times ranked

7132
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 328-354. | 6.4 | 2,188 |
| 2 | The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2320-2333. | 6.4 | 343 |
| 3 | PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. <i>Lancet</i> , The, 2017, 390, 2790-2802. | 13.7 | 274 |
| 4 | Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e511-e522. | 4.6 | 201 |
| 5 | Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2019, 20, 216-228. | 10.7 | 163 |
| 6 | ¹⁸ F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. <i>Haematologica</i> , 2006, 91, 522-9. | 3.5 | 155 |
| 7 | Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet</i> , The, 2015, 385, 1418-1427. | 13.7 | 154 |
| 8 | Positron Emission Tomographyâ€“Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2835-2845. | 1.6 | 151 |
| 9 | Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 80-94. | 10.7 | 121 |
| 10 | Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. <i>JCI Insight</i> , 2016, 1, e89631. | 5.0 | 121 |
| 11 | A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies. <i>Journal of Nuclear Medicine</i> , 2022, 63, 172-179. | 5.0 | 96 |
| 12 | PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 223-234. | 10.7 | 93 |
| 13 | Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256. | 1.6 | 73 |
| 14 | ¹⁸ F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 932-942. | 6.4 | 62 |
| 15 | Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2021, 106, 1129-1137. | 3.5 | 57 |
| 16 | Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 65-79. | 6.4 | 55 |
| 17 | Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. <i>Journal of Nuclear Medicine</i> , 2021, 62, 332-337. | 5.0 | 53 |
| 18 | Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. <i>Journal of Clinical Oncology</i> , 2022, 40, 2352-2360. | 1.6 | 53 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. <i>Leukemia</i> , 2021, 35, 143-155. | 7.2 | 52 |
| 20 | Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>PLoS ONE</i> , 2017, 12, e0169828. | 2.5 | 50 |
| 21 | Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 760-769. | 6.3 | 45 |
| 22 | Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. <i>Blood Advances</i> , 2021, 5, 2375-2384. | 5.2 | 40 |
| 23 | Active Patient Participation in the Development of an Online Intervention. <i>JMIR Research Protocols</i> , 2014, 3, e59. | 1.0 | 40 |
| 24 | Barriers and facilitators to effective communication experienced by patients with malignant lymphoma at all stages after diagnosis. <i>Psycho-Oncology</i> , 2013, 22, 2807-2814. | 2.3 | 38 |
| 25 | ⁸⁹ Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1825-1832. | 5.0 | 38 |
| 26 | 18 FDG positron emission tomography versus 67 Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 123, 454-462. | 2.5 | 37 |
| 27 | Quantitative implications of the updated EARL 2019 PET-CT performance standards. <i>EJNMMI Physics</i> , 2019, 6, 28. | 2.7 | 37 |
| 28 | Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 843-853. | 0.8 | 36 |
| 29 | The eHealth self-management application "Oncokompas" that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?. <i>Acta Oncologica</i> , 2021, 60, 403-411. | 1.8 | 34 |
| 30 | Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1167-1169. | 5.0 | 32 |
| 31 | Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. <i>Molecular Imaging and Biology</i> , 2020, 22, 1102-1110. | 2.6 | 32 |
| 32 | Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. <i>Haematologica</i> , 2020, 105, 2805-2812. | 3.5 | 30 |
| 33 | PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e398-e409. | 4.6 | 28 |
| 34 | Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2019, 104, e151-e153. | 3.5 | 27 |
| 35 | Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. <i>British Journal of Cancer</i> , 2017, 117, 306-314. | 6.4 | 26 |
| 36 | An Integrated Process and Outcome Evaluation of a Web-Based Communication Tool for Patients With Malignant Lymphoma: Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2016, 18, e206. | 4.3 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | ¹⁸ F-FDG or ³ -Deoxy- ³ - ¹⁸ F-Fluorothymidine to Detect Transformation of Follicular Lymphoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 216-221. | 5.0 | 24 |
| 38 | In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. <i>Med</i> , 2021, 2, 1171-1193.e11. | 4.4 | 24 |
| 39 | The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸ F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1424-1430. | 5.0 | 20 |
| 40 | Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 998-998. | 1.4 | 19 |
| 41 | Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments. <i>Leukemia and Lymphoma</i> , 2009, 50, 1748-1749. | 1.3 | 18 |
| 42 | Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma. <i>HemaSphere</i> , 2017, 1, e5. | 2.7 | 18 |
| 43 | Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12121. | 12.2 | 18 |
| 44 | Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7504-7504. | 1.6 | 17 |
| 45 | Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 389-395. | 5.0 | 16 |
| 46 | FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?. <i>Haematologica</i> , 2016, 101, 1279-1283. | 3.5 | 14 |
| 47 | Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. <i>Blood</i> , 2010, 116, 765-765. | 1.4 | 14 |
| 48 | Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images. <i>Molecular Imaging and Biology</i> , 2018, 20, 1025-1034. | 2.6 | 13 |
| 49 | Efficacy and cost-utility of the eHealth application ãOncokompasã™, supporting patients with incurable cancer in finding optimal palliative care, tailored to their quality of life and personal preferences: a study protocol of a randomized controlled trial. <i>BMC Palliative Care</i> , 2019, 18, 85. | 1.8 | 13 |
| 50 | Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7500-7500. | 1.6 | 13 |
| 51 | Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG) Tj ETQq1 1 0.784314 rgBT 1/2 Overlo | 4.14 | 12 |
| 52 | PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group. <i>Blood</i> , 2018, 132, 925-925. | 1.4 | 12 |
| 53 | ¹⁸ F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1001-1007. | 5.0 | 12 |
| 54 | Interobserver reproducibility of tumor uptake quantification with ⁸⁹ Zr-immuno-PET: a multicenter analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1840-1849. | 6.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989â€“2017. <i>Leukemia</i> , 2021, 35, 494-505. | 7.2 | 11 |
| 56 | Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. <i>Blood Advances</i> , 2021, 5, 2958-2964. | 5.2 | 11 |
| 57 | Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial. <i>Blood</i> , 2010, 116, 764-764. | 1.4 | 11 |
| 58 | Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial. <i>Blood</i> , 2019, 134, 1547-1547. | 1.4 | 10 |
| 59 | Self-Reported Sexual Function in Sexually Active Male Hodgkin Lymphoma Survivors. <i>Sexual Medicine</i> , 2020, 8, 428-435. | 1.6 | 9 |
| 60 | Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial. <i>Neuro-Oncology</i> , 2021, 23, 1315-1326. | 1.2 | 9 |
| 61 | Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial. <i>Lancet Regional Health - Europe</i> , The, 2022, 18, 100390. | 5.6 | 9 |
| 62 | ¹⁸ F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma. <i>EJNMMI Research</i> , 2016, 6, 46. | 2.5 | 8 |
| 63 | Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim ¹⁸ F-FDG PET in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1531-1536. | 5.0 | 8 |
| 64 | Successful Treatment of MYC rearrangement Positive Large B Cell Lymphoma Patients with R-CHOP21 Plus Lenalidomide: Results of a Multicenter Phase II HOVON Trial. <i>Blood</i> , 2018, 132, 786-786. | 1.4 | 8 |
| 65 | Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 2603-2611. | 1.6 | 7 |
| 66 | Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand. <i>EJNMMI Research</i> , 2019, 9, 95. | 2.5 | 7 |
| 67 | Potential and pitfalls of ⁸⁹ Zr-immuno-PET to assess target status: ⁸⁹ Zr-trastuzumab as an example. <i>EJNMMI Research</i> , 2021, 11, 74. | 2.5 | 6 |
| 68 | Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989â€“2018. <i>Blood Cancer Journal</i> , 2022, 12, 38. | 6.2 | 6 |
| 69 | Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer. <i>Cancer Medicine</i> , 2019, 8, 190-199. | 2.8 | 5 |
| 70 | Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , . | 0.4 | 5 |
| 71 | First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alectuzumab and Consolidated by High Dose Therapy. <i>Blood</i> , 2012, 120, 57-57. | 1.4 | 5 |
| 72 | Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1. | 6.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | PET-CT: reliable cornerstone for Hodgkin lymphoma treatment?. <i>Blood</i> , 2016, 127, 1521-1522. | 1.4 | 3 |
| 74 | Communication during haematological consultations; patientsâ€™ preferences and professionalsâ€™ performances. <i>Annals of Hematology</i> , 2016, 95, 1177-1183. | 1.8 | 3 |
| 75 | Baseline PET as prognostic marker for Hodgkin?. <i>Blood</i> , 2018, 131, 3-4. | 1.4 | 3 |
| 76 | Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkinâ€™s lymphoma: influence on long-term adverse effects (SOPHIA). <i>BMJ Open</i> , 2018, 8, e018120. | 1.9 | 3 |
| 77 | Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1655.2-1656. | 5.0 | 3 |
| 78 | The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review. <i>Cancer Imaging</i> , 2021, 21, 36. | 2.8 | 3 |
| 79 | First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alectuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,. <i>Blood</i> , 2011, 118, 4110-4110. | 1.4 | 3 |
| 80 | Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7507-7507. | 1.6 | 3 |
| 81 | Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data. <i>Blood</i> , 2021, 138, 879-879. | 1.4 | 3 |
| 82 | Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. <i>Blood</i> , 2018, 132, 1677-1677. | 1.4 | 2 |
| 83 | The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791. | 3.7 | 2 |
| 84 | Bloodâ€™s circulating EVâ€™miRNAs, serum TARC, and quantitative FDGâ€™PET features in classical Hodgkin lymphoma. <i>EJHaem</i> , 2022, 3, 908-912. | 1.0 | 2 |
| 85 | Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands. <i>Blood Cancer Journal</i> , 2021, 11, 87. | 6.2 | 1 |
| 86 | 18f-FDG PET/CT Baseline Radiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2020, 136, 27-28. | 1.4 | 1 |
| 87 | 90yttrium Ibritumomab Tiuxetan-BEAM Followed by Autologous Stem Cell Transplantation Significantly Improves Overall Survival After Rituximab Containing Induction Therapy in Patients with High-Risk Aggressive B Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 3078-3078. | 1.4 | 1 |
| 88 | 3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body 18F-Fluorodeoxyglucose and 89Zr-Rituximab PET Scans. <i>Diagnostics</i> , 2022, 12, 596. | 2.6 | 1 |
| 89 | Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 1346. | 3.7 | 1 |
| 90 | Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma,. <i>Blood</i> , 2011, 118, 3658-3658. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Immunologic Recovery Following Consolidation with ⁹⁰ Yttrium Ibritumomab Tiuxetan (Zevalin®)-BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014, 124, 5882-5882. | 1.4 | 0 |
| 92 | Long-term survival of gastrointestinal cancer diagnosed in Hodgkin lymphoma survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-40. | 1.6 | 0 |
| 93 | High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial. <i>Blood</i> , 2021, 138, 1414-1414. | 1.4 | 0 |
| 94 | Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , . | 0.4 | 0 |
| 95 | Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020, 136, 34-35. | 1.4 | 0 |
| 96 | Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020, 136, 5-6. | 1.4 | 0 |
| 97 | Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment. <i>HemaSphere</i> , 2022, 6, e749. | 2.7 | 0 |